证券代码：835892 证券简称：中科美菱 公告编号：2024-008 中科美菱低温科技股份有限公司 第三届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 3 月 21 日 2.会议召开地点：公司会议室 3.会议召开方式：现场方式 4.发出监事会会议通知的时间和方式：2024 年 3 月 11 日以电子邮件方式发出 5.会议主持人：监事会主席杨鲲先生 6.召开情况合法、合规、合章程性说明： 本次会议的召集与召开、议案的审议程序等，均符合《公司法》《证券法》 《公司章程》及相关法律、法规、规范性文件的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《2023 年年度报告及年度报告摘要》 1.议案内容： 监事会认为，公司董事会编制和审议《2023 年年度报告》的程序符合法 律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市 ...

中科美菱低温科技有限公司 2023 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | | In I Tim I The UN K 云永中和会计师事务所 XYZH/202 ICDAA7F0009 中科美夢低温科技股份有限公司 中科美菱低温科技股份有限公司全体股东: 我们按照中国注册会计师审计准则审计了中科美菱低温科技股份有限公司(以下简 称中科美菱公司)2023年度财务报表,包括2023年12月31日的合并及母公司资产负 债表、2023年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东 权益变动表以及财务报表附注,并于2024年3月21日出具了 XYZH/2024CDAA7B0064 号 无保留意见的审计报告、 根据中国证券监督管理委员会《上市公司监管指引第8号 -- 上市公司资金往来、 对外担保的监管要求》(证监会公告[2022]26号),以及北京证券交易所相关披露的要求, 中科美菱公司编制了本专项说明所附的中科美菱公司 2023年度非经营性资金占用及其 ...

中科美菱低温科技股份有限公司 关于 2024 年度董事、监事及高级管理人员薪酬方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 中科美菱低温科技股份有限公司（以下简称"公司"或"本公司"）根据相 关法律法规、《公司章程》等相关制度的规定，结合公司实际经营情况，参考所 处行业的薪酬水平，拟定了 2024 年度董事、监事和高级管理人员薪酬方案。现 将方案具体内容公告如下： 一、方案适用对象及适用期限 证券代码：835892 证券简称：中科美菱 公告编号：2024-018 适用对象：公司 2024 年度任期内的董事、监事和高级管理人员。 适用期限：2024 年 1 月 1 日至 2024 年 12 月 31 日。 二、薪酬方案 （一）董事薪酬方案 1.独立董事津贴标准。 公司 2024 年度独立董事津贴：每人 10 万元/年（税前）。 2.非独立董事薪酬方案。 在公司担任具体行政职务的非独立董事，2024 年度薪酬按照其在公司所担 任的行政岗位领取薪酬，不领取董事职务报酬。按照国家和地方的有关规定， ...

证券代码：835892 证券简称：中科美菱 公告编号：2024-011 | 独立董 | 应参加董 | 实际出席 | 委托出席 | 缺席董 | 是否连续两次未 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | | 事姓名 | 事会次数 | 董事会次 | 董事会次 | 事会次 | 亲自参加董事会 | 大会次数 | | | | 数 | 数 | 数 | 会议 | | | 王虹 | 7 | 7 | 0 | 0 | 否 | 2 | 2023 年度，本着勤勉务实和诚信负责的原则，本人认真审阅会议材料，参与 各议案的讨论并提出合理建议，并与公司经营管理层充分沟通，从而为董事会的 正确决策发挥积极作用。经认真审议后，2023 年度本人对公司董事会各项议案 均投赞成票，无反对票及弃权票。 （二）出席董事会专门委员会的情况 报告期内，公司共召开 4 次董事会审计委员会会议，1 次董事会提名委员会 会议。本人不存在缺席或委托其他董事代为出席应出席的专门委员会会议并行使 中科美菱低温科技股份有限公司 2023 年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和 ...

证券代码：835892 证券简称：中科美菱 公告编号：2024-012 中科美菱低温科技股份有限公司 2023 年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 2023 年度，作为中科美菱低温科技股份有限公司（以下简称"公司"）的第 三届董事会独立董事，本人严格按照《公司法》《证券法》《上市公司独立董事 管理办法》等法律法规和《公司章程》《独立董事制度》等规定，勤勉、忠实、 尽责地履行职责，充分发挥独立董事作用，维护公司整体利益和全体股东尤其是 中小股东的合法权益。现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、出席会议情况 （一）出席董事会及股东大会的情况 2023 年度，本人出席会议的情况如下： | 独立董 | 应参加董 | 实际出席 | 委托出席 | 缺席董 | 是否连续两次未 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | | 事姓名 | 事会次数 | 董事会次 | 董事会次 | 事会次 | 亲自参加董 ...

证券代码：835892 证券简称：中科美菱 公告编号：2024-019 中科美菱低温科技股份有限公司 董事会关于独立董事独立性自查情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 根据中国证券监督管理委员会《上市公司独立董事管理办法》《北京证券交 易所股票上市规则（试行）》等要求，中科美菱低温科技股份有限公司（以下简 称"公司"）董事会就公司在任独立董事王虹女士、竺长安先生、向东先生的独 立性情况进行评估并出具如下专项意见： 经核查公司独立董事王虹女士、竺长安先生、向东先生的任职经历以及签署 的相关自查文件，确认上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况， 符合《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管指引第 1 号——独立董事（2023 年修订）》中对独立董事独立性的相关要求。 中科美菱低温科技股份有限公司 董事会 202 ...

Financial Performance - In 2023, Zhongke Meiling reported operating revenue of ¥302,785,719.33, a decrease of 25.51% compared to ¥406,489,091.83 in 2022[28]. - The net profit attributable to shareholders was ¥16,126,507.82, down 69.33% from ¥52,586,940.63 in the previous year[28]. - The gross profit margin improved slightly to 38.32% in 2023 from 38.17% in 2022[28]. - The basic earnings per share decreased by 75.72% to ¥0.1667 from ¥0.6867 in 2022[28]. - The weighted average return on net assets attributable to shareholders dropped to 2.69% from 17.54% in 2022[28]. - The net profit after deducting non-recurring gains and losses was ¥3,486,531.14, a decline of 91.09% from ¥39,149,709.74 in the previous year[28]. - Total assets decreased by 9.21% from 807,126,097.66 to 732,823,882.42[29]. - Total liabilities decreased by 36.25% from 205,972,761.11 to 131,303,910.06[29]. - Cash flow from operating activities improved by 74.46%, from -38,010,376.20 to -9,706,149.56[29]. - The current ratio increased by 43.35% from 3.41 to 4.89[29]. - The interest coverage ratio decreased significantly by 88.95% from 117.98 to 38.02[29]. - The company achieved a net profit of 16,126,507.82, with a basic earnings per share of 0.1667[32]. - The company reported a significant increase in investment income, rising 216.92% to 4,869,782.42 CNY from 1,536,604.68 CNY in 2022[54]. - The company’s main business revenue decreased by 25.49% year-on-year to ¥298,620,046.22, primarily due to a slowdown in large-scale procurement of low-temperature storage equipment[58]. - Net profit decreased by 69.33% year-on-year, driven by a decline in operating income, increased R&D expenses, and reduced government subsidies[56]. - The revenue from low-temperature storage equipment fell by 30.60% year-on-year, mainly due to insufficient industry demand and a weak market outlook[62]. Product Development and Innovation - The company launched a new brand, MEGSTEMAN, along with four new product series in December 2023, marking a significant milestone in the life sciences sector[6]. - The company launched the third-generation medical refrigeration box and the world's first -180℃ compression refrigeration ultra-low temperature biological storage device, filling a market gap[43]. - The company is focusing on the life sciences sector and accelerating the development and launch of strategic new products such as biological safety cabinets and liquid nitrogen biological containers[43]. - The company is developing a dual-system refrigeration technology to achieve higher energy efficiency and replace liquid nitrogen backup, addressing overseas market demands for -40℃ to -80℃ products[88]. - The company aims to optimize the performance of its existing ultra-low temperature products through the development of a three-stage throttling technology, enhancing system stability and reliability[88]. - The company is advancing a project focused on low-temperature thermal conductive materials for medical refrigeration, which is expected to significantly improve product insulation and operational efficiency[89]. - The company is working on solar-powered refrigeration technology that operates independently of the power grid, targeting remote areas and expanding market opportunities[89]. - The company is enhancing its medical refrigeration products with IoT technology, aiming to improve management and monitoring capabilities, thus increasing market competitiveness[89]. - The company is collaborating with Anhui Blatter Intelligent Technology on the development and industrialization of an ultra-low temperature intelligent biological sample library[90]. - The company is also partnering with Shanghai Qiyao Power Technology on the ultra-low temperature Stirling cooler project, indicating a focus on innovative cooling solutions[90]. - The company is in the prototype stage for a new laboratory centrifuge product line, aimed at meeting strong market demand for centrifuge equipment[89]. - The company is developing a smart biological sample storage system that enhances safety and efficiency in sample management, addressing market needs for high-quality storage solutions[89]. Research and Development - Research and development expenses increased by 17.91% to 33,335,275.72 CNY, reflecting the company's commitment to innovation[54]. - R&D expenditure for 2023 amounted to ¥33,335,275.72, representing 11.01% of operating revenue, an increase from 6.96% in the previous year[85]. - The company holds a total of 363 patents, up from 306 in the previous period, including 18 invention patents compared to 12 previously[86]. - The company has implemented a tax deduction policy for R&D expenses, allowing for a 100% pre-tax deduction for actual R&D costs incurred[84]. Market Strategy and Operations - The company is focusing on internationalization of medical products in collaboration with SGS[7]. - The domestic marketing strategy emphasizes user-centric channel system construction and service marketing upgrades, addressing logistical challenges[45]. - The medical device industry is expected to continue growing due to increasing healthcare spending and the expansion of the biopharmaceutical sector[46]. - National policies are providing significant support for the medical device industry, encouraging innovation and domestic equipment replacement[48]. - The company is transitioning from low-margin C-end business to focus on higher-margin products, impacting overall business performance[42]. - The company aims to enhance customer satisfaction through improved after-sales service and localized support[45]. - The company plans to optimize its strategic layout by focusing on high-quality resources and gradually exiting low-margin, low-price C-end businesses[63]. - The company is committed to establishing a comprehensive deep-cooling storage technology system to support the growing demand for ultra-low temperature storage solutions[89]. Corporate Governance and Compliance - The company has established a governance structure to prevent conflicts of interest from major shareholders[110]. - The company has passed the re-certification as a high-tech enterprise, maintaining a 15% corporate income tax rate for three years[110]. - The company has implemented measures to reduce related party transactions to mitigate operational risks[110]. - The company’s governance practices align with the requirements of the Company Law and other relevant regulations, with no violations reported[184]. - The company has established a robust internal control system, ensuring compliance and effective management of operations, with no significant internal control deficiencies reported during the period[195]. - The company emphasizes investor relations management, ensuring timely and accurate information disclosure through various channels[198]. Social Responsibility and Sustainability - The company established a scholarship at Tsinghua University to support education in life sciences, reflecting its commitment to social responsibility[97]. - The company donated an automated vaccination workstation valued at RMB 1.15 million to enhance vaccination efficiency and safety[98]. - The company upgraded its waste gas treatment technology, improving the efficiency of organic waste gas collection and reducing emissions[99]. - The company has implemented a paperless office initiative to reduce paper usage and promote environmental sustainability[99]. - Energy conservation and environmental protection are becoming critical evaluation criteria for products, aligning with national goals for carbon neutrality and sustainability[103]. Financial Management - The company raised a total of ¥386,923,744 through public offerings, with ¥59,578,496.42 utilized during the reporting period[149]. - The company distributed cash dividends of ¥1.8 per 10 shares, totaling ¥17,411,568.12 to shareholders[153]. - The company has short-term loans totaling ¥10,000,000 with an interest rate of 3.30%[152]. - The company has not changed the purpose of the raised funds during the reporting period, adhering to regulatory requirements[150]. - The company has committed to purchasing its own shares using the performance incentive funds granted to executives[159]. Employee and Shareholder Relations - The total number of employees decreased from 746 to 614, a reduction of 132 employees, primarily in production and sales roles[166][167]. - The company’s total shareholding by executives increased to 3,177,993 shares, representing 3.2855% of total shares[160]. - The company has implemented a competitive salary policy, including basic, seniority, and performance-based salaries, along with additional benefits such as commercial insurance and health check-ups[168]. - The company’s independent directors receive an annual allowance of RMB 100,000, as approved by the shareholders' meeting[165]. - The company has established a harmonious labor relationship by protecting employee rights and interests through various management systems[96].

证券代码：835892 证券简称：中科美菱 公告编号：2024-023 中科美菱低温科技股份有限公司 董事会审计委员会 2023 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 公司董事会审计委员会根据《公司法》《证券法》《上市公司独立董事管理 办法》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等法律法 规及规则指引要求，在 2023 年度内认真履职。现将本年度履职情况汇报如下： 一、基本情况 公司董事会审计委员会由 3 名不在公司担任高级管理人员的独立董事组 成，分别为王虹女士、竺长安先生、向东先生，其中王虹女士为会计专业人 事，担任公司审计委员会主任委员（召集人）。 二、会议召开情况 2023 年度，公司董事会审计委员会共召开 4 次会议，具体情况如下： | 会议名称 | | 召开时间 | | | | 审议事项 | 表决结果 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第三届董事会审计 ...

Financial Performance - The company's net profit for 2023 is expected to be approximately ¥1,612.65 million, a decrease of 69.33% compared to ¥5,258.69 million in the previous year[3]. - The decline in net profit is primarily attributed to a decrease in operating revenue, increased R&D expenses, and a significant reduction in government subsidies received[4]. - Government subsidies received in 2023 have decreased significantly compared to 2022, impacting overall profitability[5]. Strategic Initiatives - The company has optimized its strategic layout by exiting low-margin, low-price C-end businesses, leading to a more focused resource allocation[4]. - The company has increased its R&D investment, achieving significant breakthroughs in new technologies such as efficient refrigeration and ultra-low temperature storage, enhancing product stability and reliability[5]. - The company is advancing automation technology, biosafety, liquid nitrogen storage, and centrifugal technology as part of its new product and technology development strategy[5]. Investment Caution - The performance forecast is based on preliminary financial data and has not been audited by an accounting firm, thus investors are advised to be cautious regarding investment risks[6].

Financial Performance - The company's operating revenue for 2023 was ¥302,800,718.15, a decrease of 25.51% compared to the previous year[3] - Net profit attributable to shareholders was ¥16,126,507.82, down 69.33% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,557,755.37, a decline of 90.91% compared to the previous year[4] - Basic earnings per share decreased to ¥0.1667, down 75.72% year-on-year[3] - Total assets at the end of the reporting period were ¥733,204,824.36, a decrease of 9.16% from the beginning of the period[4] - The company's equity attributable to shareholders increased by 0.06% to ¥601,519,972.36[4] Revenue Decline Factors - The decline in revenue was primarily due to a slowdown in emergency procurement in the medical and biopharmaceutical sectors and a strategic exit from low-margin C-end businesses[5] - Government subsidies received in 2023 were significantly lower than in 2022, impacting net profit[5] Research and Development - The company has made significant R&D investments, achieving breakthroughs in efficient refrigeration technology and new product development[5] - The company is focusing on diversifying its product strategy in the biomedical field through technological advancements[5]